头孢吡肟单独及联合使用对囊性纤维化患者铜绿假单胞菌和洋葱伯克霍尔德菌临床分离株的比较活性。
Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
作者信息
Bosso J A, Saxon B A, Matsen J M
机构信息
College of Pharmacy, University of Houston, Texas.
出版信息
Antimicrob Agents Chemother. 1991 Apr;35(4):783-4. doi: 10.1128/AAC.35.4.783.
Abstract
The comparative in vitro activity and synergy of cefepime were evaluated with clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. The activity of cefepime, both alone and in combination, was comparable to those of other antibiotics. The clinical efficacy of cefepime in cystic fibrosis patients merits investigation.
摘要
对头孢吡肟与来自囊性纤维化患者的铜绿假单胞菌和洋葱伯克霍尔德菌临床分离株的体外活性及协同作用进行了比较评估。头孢吡肟单独使用及联合使用时的活性与其他抗生素相当。头孢吡肟在囊性纤维化患者中的临床疗效值得研究。
相似文献
1
Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.头孢吡肟单独及联合使用对囊性纤维化患者铜绿假单胞菌和洋葱伯克霍尔德菌临床分离株的比较活性。
Antimicrob Agents Chemother. 1991 Apr;35(4):783-4. doi: 10.1128/AAC.35.4.783.
2
3
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.美罗培南、亚胺培南、头孢吡肟和头孢他啶对囊性纤维化患者分离出的铜绿假单胞菌的体外活性。
J Antimicrob Chemother. 2000 Jun;45(6):899-901. doi: 10.1093/jac/45.6.899.
4
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.多利培南对来自囊性纤维化和非囊性纤维化患者的铜绿假单胞菌和洋葱伯克霍尔德菌分离株的体外活性。
Antimicrob Agents Chemother. 2006 Feb;50(2):819-21. doi: 10.1128/AAC.50.2.819-821.2006.
5
Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis.头孢匹胺（HR - 810）与四种抗假单胞菌β - 内酰胺类药物对囊性纤维化患儿分离出的假单胞菌的比较。
J Antimicrob Chemother. 1985 May;15(5):545-9. doi: 10.1093/jac/15.5.545.
6
Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.新型C-3取代头孢菌素与妥布霉素对铜绿假单胞菌和洋葱伯克霍尔德菌的协同作用。
Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4):343-9. doi: 10.1016/0732-8893(89)90101-6.
7
Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.囊性纤维化患者中铜绿假单胞菌对头孢吡肟和头孢他啶的敏感性
Pharmacotherapy. 2001 Nov;21(11):1320-4. doi: 10.1592/phco.21.17.1320.34420.
8
In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.BMY-28142对儿科病原体的体外活性，包括来自囊性纤维化痰液的分离株。
Antimicrob Agents Chemother. 1985 Jul;28(1):58-63. doi: 10.1128/AAC.28.1.58.
9
In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.环丙沙星及其他抗菌药物对囊性纤维化患者铜绿假单胞菌和洋葱伯克霍尔德菌的体外活性。
J Antimicrob Chemother. 1985 Jun;15(6):679-84. doi: 10.1093/jac/15.6.679.
10
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
Pathol Biol (Paris). 2003 Apr;51(3):135-42. doi: 10.1016/s0369-8114(03)00023-3.
引用本文的文献
1
Dual beta-lactam treatment: Pros and cons.双β-内酰胺治疗：利弊
Porto Biomed J. 2022 Oct 24;7(5):e189. doi: 10.1097/j.pbj.0000000000000189. eCollection 2022 Sep-Oct.
2
Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.囊性纤维化患者的感染：耐药性与治疗方法
Front Microbiol. 2017 Aug 22;8:1592. doi: 10.3389/fmicb.2017.01592. eCollection 2017.
3
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.铜绿假单胞菌感染囊性纤维化患者：临床影响、诊断和治疗的科学证据。
J Bras Pneumol. 2013 Jun-Aug;39(4):495-512. doi: 10.1590/S1806-37132013000400015.
4
Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.在体外药效学感染模型中，头孢吡肟单独及与多种抗菌药物联合对耐甲氧西林金黄色葡萄球菌的药效学研究
Antimicrob Agents Chemother. 2005 Jan;49(1):302-8. doi: 10.1128/AAC.49.1.302-308.2005.
5
In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.抗生素组合对铜绿假单胞菌临床分离株的体外活性
Kaohsiung J Med Sci. 2004 Jun;20(6):261-7. doi: 10.1016/s1607-551x(09)70116-0.
6
Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.使用E试验评估抗生素联合用药对囊性纤维化患者洋葱伯克霍尔德菌复合体分离株的协同作用。
Eur J Clin Microbiol Infect Dis. 2003 Jan;22(1):28-34. doi: 10.1007/s10096-002-0852-8. Epub 2003 Jan 25.
7
Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.头孢吡肟-氨曲南：一种用于铜绿假单胞菌的独特双β-内酰胺组合。
Antimicrob Agents Chemother. 1998 Jul;42(7):1610-9. doi: 10.1128/AAC.42.7.1610.
8
Pharmacokinetics of cefepime in cystic fibrosis patients.头孢吡肟在囊性纤维化患者中的药代动力学。
Antimicrob Agents Chemother. 1993 Jul;37(7):1414-6. doi: 10.1128/AAC.37.7.1414.
9
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢吡肟：抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.
本文引用的文献
1
Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.将BMY-28142、头孢布宗和头孢匹胺的抗菌活性与其他头孢菌素的抗菌活性进行比较。
Antimicrob Agents Chemother. 1984 Oct;26(4):585-90. doi: 10.1128/AAC.26.4.585.
2
Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
J Pediatr. 1983 Aug;103(2):320-4. doi: 10.1016/s0022-3476(83)80377-1.
3
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
4
Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.新型头孢菌素BMY 28142与其他广谱β-内酰胺类抗生素的比较。
Antimicrob Agents Chemother. 1985 Feb;27(2):207-16. doi: 10.1128/AAC.27.2.207.
5
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.头孢他啶与替卡西林及妥布霉素治疗囊性纤维化患者急性呼吸加重的对照试验。
Pediatr Infect Dis. 1985 Mar-Apr;4(2):172-7. doi: 10.1097/00006454-198503000-00012.
6
Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.铜绿假单胞菌对头孢吡肟、头孢他啶和头孢噻肟的体外耐药频率。
Antimicrob Agents Chemother. 1988 Sep;32(9):1443-5. doi: 10.1128/AAC.32.9.1443.
7
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
Pediatr Infect Dis J. 1988 Mar;7(3):171-6. doi: 10.1097/00006454-198803000-00008.
8
Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.囊性纤维化的抗假单胞菌治疗：氨曲南与阿米卡星对比头孢他啶与阿米卡星静脉给药后序贯口服环丙沙星
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):858-65. doi: 10.1007/BF01963771.
9
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.头孢吡肟对头孢他啶和头孢噻肟耐药革兰阴性菌的活性及其与β-内酰胺酶水平的关系。
Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498.
Zotero 插件